Peptide Receptor Radionuclide Therapy with Indigenous
Am J Nucl Med Mol Imaging 2020;10(4):178-211 www.ajnmmi.us /ISSN:2160-8407/ajnmmi0115339 Review Article One decade of ‘Bench-to-Bedside’ peptide receptor radionuclide therapy with indigenous [177Lu]Lu-DOTATATE obtained through ‘Direct’ neutron activation route: lessons learnt including practice evolution in an Indian setting Sandip Basu1,2, Sudipta Chakraborty2,3, Rahul V Parghane1,2, Kamaldeep2,4, Rohit Ranade1,2, Pradeep Thapa1,2, Ramesh V Asopa1,2, Geeta Sonawane1,2, Swapna Nabar1,2, Hemant Shimpi1,2, Ashok Chandak1,2, Vimalnath KV3, Vikas Ostwal2,5, Anant Ramaswamy2,5, Manish Bhandare2,6, Vikram Chaudhari2,6, Shailesh V Shrikhande2,6, Bhawna Sirohi5,7, Ashutosh Dash2,3, Sharmila Banerjee1,2 1Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Parel, Mumbai, India; 2Homi Bhabha National Institute, Mumbai, India; 3Radiopharmaceuticals Division, BARC, Mumbai, India; 4Health Physics Division, Bhabha Atomic Research Centre, Mumbai, India; 5Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India; 6Department of Surgical Oncology, Gastrointestinal and Hepato- Pancreato-Biliary Service, Tata Memorial Hospital, Mumbai, India; 7Apollo Proton Cancer Centre, Chennai, India Received May 30, 2020; Accepted August 14, 2020; Epub August 25, 2020; Published August 30, 2020 Abstract: The present treatise chronicles one decade of experience pertaining to clinical PRRT services in a large- volume tertiary cancer care centre in India delivering over 4,000 therapies, an exemplar of successful
[Show full text]